RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $25.67 Average Price Target from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has been assigned an average rating of “Moderate Buy” from the twelve ratings firms that are covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $25.67.

RAPT has been the subject of several research reports. Cantor Fitzgerald cut shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, February 20th. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a report on Wednesday, April 10th. Barclays cut their target price on RAPT Therapeutics from $35.00 to $13.00 and set an “overweight” rating for the company in a research note on Wednesday, February 21st. Wolfe Research started coverage on shares of RAPT Therapeutics in a research note on Thursday, February 15th. They set an “outperform” rating and a $39.00 price target on the stock. Finally, Leerink Partnrs cut shares of RAPT Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 21st.

Institutional Investors Weigh In On RAPT Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in RAPT. China Universal Asset Management Co. Ltd. increased its position in shares of RAPT Therapeutics by 347.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,981 shares of the company’s stock worth $99,000 after purchasing an additional 3,092 shares in the last quarter. Exchange Traded Concepts LLC raised its stake in shares of RAPT Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,190 shares of the company’s stock valued at $179,000 after acquiring an additional 1,824 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of RAPT Therapeutics in the fourth quarter valued at approximately $233,000. SG Americas Securities LLC acquired a new position in shares of RAPT Therapeutics in the 4th quarter worth approximately $244,000. Finally, Chesapeake Capital Corp IL bought a new stake in RAPT Therapeutics during the 4th quarter worth approximately $254,000. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Stock Up 6.2 %

Shares of NASDAQ RAPT opened at $8.18 on Monday. RAPT Therapeutics has a 12 month low of $6.86 and a 12 month high of $27.35. The company has a market cap of $284.66 million, a P/E ratio of -2.69 and a beta of 0.47. The business’s 50 day moving average is $8.49 and its two-hundred day moving average is $15.39.

RAPT Therapeutics (NASDAQ:RAPT) last released its earnings results on Thursday, March 7th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.05. Sell-side analysts expect that RAPT Therapeutics will post -3.19 earnings per share for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.